Tivozanib

LG Chem’s New US Acquisition AVEO Oncology Sets Sights On Being Global Top 20 Innovative Oncology Company

Retrieved on: 
Wednesday, March 8, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Cachexia, LG, Communication, Lead, Acquisition, Renal cell carcinoma, Growth, Clinical trial, USD, Malnutrition, Head, Kidney cancer, Patient, Cancer, Multimedia, LG Chem, FDA, Human, Tivozanib, Nursing, Interior design, Pharmaceutical industry

AVEO Oncology, a Boston-based oncology company acquired by LG Chem for USD 571 million, has laid out a blueprint to become a global top 20 oncology-focused biopharmaceutical company within five years.

Key Points: 
  • AVEO Oncology, a Boston-based oncology company acquired by LG Chem for USD 571 million, has laid out a blueprint to become a global top 20 oncology-focused biopharmaceutical company within five years.
  • With LG Chem’s full support, AVEO plans to boost its existing oncology business significantly and to become an innovative oncology company that can exert significant influence in the global markets.
  • CEO Shin, in his first trip to the U.S. since the completion of the AVEO Oncology acquisition, was accompanied by 20 executives and employees of LG Chem including: Dr.
  • The LG Chem representatives, all in navy blue hoodies sporting the new “AVEO Oncology, an LG Chem company” logo, were greeted with warm cheers and applause as they were introduced on the stage.

AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma

Retrieved on: 
Thursday, July 8, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cancer treatments, Clinical medicine, Chemical compounds, Kidney cancer, Antineoplastic drugs, Renal cell carcinoma, Orphan drugs, Tivozanib, P110δ, Phosphoinositide 3-kinase inhibitor, FOTIVDA® (tivozanib), AVEO Pharmaceuticals, Inc., FOTIVDA® (TIVOZANIB), AVEO PHARMACEUTICALS, INC.

AVEO's management team will provide a brief company overview and discuss the market opportunity and launch strategy for FOTIVDA.

Key Points: 
  • AVEO's management team will provide a brief company overview and discuss the market opportunity and launch strategy for FOTIVDA.
  • AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA on March 10, 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
  • FOTIVDA has been shown to significantly reduce regulatory T-cell production in preclinical models.1 FOTIVDA was discovered by Kyowa Kirin.
  • FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

AVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines

Retrieved on: 
Monday, March 29, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Health, Medicine, National Comprehensive Cancer Network, NCCN, Tivozanib, Oncology, Medical guideline, Clinical trial, Journal of the National Comprehensive Cancer Network, FOTIVDA® (tivozanib), Advanced Renal Cell Carcinoma, AVEO Pharmaceuticals, Inc.

AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA (tivozanib) as a recommended regimen for subsequent therapy.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA (tivozanib) as a recommended regimen for subsequent therapy.
  • The NCCN Clinical Practice Guidelines are the recognized standard for clinical policy in cancer care and are developed through review of evidence and recommendations from physicians and oncology researchers.
  • The current NCCN RCC guidelines categorically make treatment recommendations for first-line or subsequent therapy options for RCC patients.
  • The approval was also supported by three additional trials in RCC and included safety data from over 1,000 clinical trial subjects.

AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA® (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance

Retrieved on: 
Monday, March 22, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical medicine, Medicine, Cancer, Kidney cancer, Cancer treatments, Renal cell carcinoma, Tivozanib, P110δ, Phosphoinositide 3-kinase inhibitor, FOTIVDA® (tivozanib), Advanced Renal Cell Carcinoma, AVEO Pharmaceuticals, Inc.

We are thrilled to begin bringing FOTIVDA to patients battling relapsed or refractory kidney cancer, said Michael Bailey, president and chief executive officer of AVEO.

Key Points: 
  • We are thrilled to begin bringing FOTIVDA to patients battling relapsed or refractory kidney cancer, said Michael Bailey, president and chief executive officer of AVEO.
  • We are keenly focused on ensuring that FOTIVDA is available to as many appropriate patients as possible, said Mike Ferraresso, chief commercial officer of AVEO.
  • AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA on March 10, 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
  • FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 16, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical trials, Cancer treatments, Clinical medicine, Drugs, Ureas, Monoclonal antibodies, Antineoplastic drugs, Breakthrough therapy, Tivozanib, Nivolumab, Hepatocellular carcinoma, FOTIVDA® (tivozanib), Advanced Renal Cell Carcinoma, AVEO Pharmaceuticals, Inc.

AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update.
  • Results from Phase 1b Portion of DEDUCTIVE Study in Hepatocellular Carcinoma (HCC) Presented at 2021 ASCO GI Cancer Symposium.
  • Results from Phase 1b/2 TiNivo Study of Tivozanib in Combination with OPDIVO (nivolumab) in RCC Published in Annals of Oncology.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

FOTIVDA® (tivozanib) Now Approved for the Treatment of Relapsed/Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies; Onco360® Selected as Specialty Pharmacy Partner

Retrieved on: 
Friday, March 12, 2021
Hospitals, Clinical trials, Biotechnology, Other Health, Managed care, Health, Pharmaceutical, General Health, Oncology, Health sciences, Medicinal chemistry, Chemical compounds, Life sciences, Kidney cancer, Specialty drugs, Renal cell carcinoma, Tivozanib, Specialty pharmacy, Therapy, Pharmacy, Thomas Hutson

Onco360, the nations largest independent Oncology Pharmacy, has been selected by AVEO Oncology to be a specialty pharmacy partner for FOTIVDA (tivozanib), a new oral treatment for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

Key Points: 
  • Onco360, the nations largest independent Oncology Pharmacy, has been selected by AVEO Oncology to be a specialty pharmacy partner for FOTIVDA (tivozanib), a new oral treatment for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
  • Onco360 is excited to be selected as a specialty pharmacy provider for FOTIVDA patients, said Benito Fernandez, Chief Commercial Officer, Onco360.
  • The recent approval of FOTIVDA unlocks a new therapy option for treatment-experienced patients with previously treated advanced RCC who have limited treatment options.
  • As a provider of this key treatment, Onco360 can support the highly specialized needs of RCC patients and their physicians across the US.

AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility

Retrieved on: 
Thursday, March 11, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cars, Chemical compounds, Motor vehicles, Fixed-income securities, Structured finance, Hatchbacks, Sedans, Subcompact cars, Tivozanib, Tranche, Chevrolet Aveo, New York Stock Exchange

AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC, Hercules) and its affiliates.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC, Hercules) and its affiliates.
  • This second tranche was made available in connection with the recent U.S. Food and Drug Administration (FDA) approval of FOTIVDA (tivozanib).
  • With the closing of the second tranche, AVEO has drawn down a total of $35 million under its loan and security agreement with Hercules.
  • An additional $5 million tranche becomes available if net product revenues of FOTIVDA reach $20 million within a specified time frame, and the final $5 million tranche would be available after that time upon the lenders consent.

AVEO Announces Appointment of Mike Ferraresso to Chief Commercial Officer

Retrieved on: 
Wednesday, March 10, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Cars, Chemical compounds, Motor vehicles, Hatchbacks, Sedans, Subcompact cars, Aveos Fleet Performance, Avianca, Chevrolet Aveo, Tivozanib, FOTIVDA® (tivozanib), AVEO Pharmaceuticals, Inc.

AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer.

Key Points: 
  • AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer.
  • Mr. Ferraresso will be responsible for managing AVEOs commercial strategy and operations, including the commercialization of FOTIVDA (tivozanib).
  • Directly on the heels of FOTIVDAs approval, it is a pleasure to announce Mikes appointment to chief commercial officer, said Michael Bailey, president and chief executive officer of AVEO.
  • Mr. Ferraresso, who joined AVEO in December 2017, most recently served as senior vice president, business analytics and commercial operations.

AVEO Oncology Announces Presentation of Key Subgroup and Quality of Life Analyses from the Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

Retrieved on: 
Thursday, February 11, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Chemical compounds, Organic compounds, Cars, Isoxazoles, Quinolines, Tivozanib, Ureas, Axitinib, Tolerability, Vascular endothelial growth factor, Chevrolet Aveo, Tivozanib (FOTIVDA, AVEO Pharmaceuticals, Inc.

Of note, sequencing data suggest differential activity between tivozanib and axitinib, despite both being potent and selective VEGF TKIs.

Key Points: 
  • Of note, sequencing data suggest differential activity between tivozanib and axitinib, despite both being potent and selective VEGF TKIs.
  • These data suggest that tivozanib may convey tolerability advantages as measured by a patient-centered health-related patient quality of life.
  • AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

AVEO Oncology Highlights Recent Progress and 2021 Outlook

Retrieved on: 
Thursday, January 7, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cars, Cancer treatments, Drugs, Monoclonal antibodies, Hatchbacks, Sedans, Subcompact cars, Breakthrough therapy, Tivozanib, Nivolumab, Tivozanib (FOTIVDA, AVEO Pharmaceuticals, Inc.

AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook.
  • We believe 2021 will be a transformational year for AVEO, and we look forward to delivering on a number of milestones designed to enhance our long-term value.
  • Results from Phase 1b/2 TiNivo Study of Tivozanib in Combination with OPDIVO (nivolumab) in RCC Published in Annals of Oncology.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.